We have collected information about Hyaluronidase Drug Delivery for you. Follow the links to find out details on Hyaluronidase Drug Delivery.
https://www.mayoclinic.org/drugs-supplements/hyaluronidase-injection-route-subcutaneous-route/description/drg-20064183
Hyaluronidase injection is a spreading substance. It is used with other medicines given under the skin to improve their uptake by the body. This method of drug delivery is only used when the drug cannot be given by injection into a vein. Hyaluronidase injection is …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394283/
Feb 11, 2019 · ENHANZE ® drug delivery technology is based on the proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20; Halozyme Therapeutics, Inc.) that facilitates the subcutaneous (SC) delivery of co‐administered therapeutics. rHuPH20 works by degrading the glycosaminoglycan hyaluronan (HA), which plays a role in resistance to bulk fluid flow in the SC space, limiting large volume SC drug delivery…Author: Kenneth W. Locke, Daniel C. Maneval, Michael J. LaBarre
https://www.drugs.com/cons/hyaluronidase-subcutaneous-injection.html
Sep 05, 2019 · Hyaluronidase injection is a spreading substance. It is used with other medicines given under the skin to improve their uptake by the body. This method of drug delivery is only used when the drug cannot be given by injection into a vein.5.5/10
https://link.springer.com/article/10.1007%2Fs12274-016-1328-y
Nov 10, 2016 · By co-embedding the breast tumor cell-penetrating peptide (PEGA-pVEC) and hyaluronic acid (HA) as a targeting media, novel cascaded targeting nanoparticles (HACT NPs) were created on a rattle mesoporous silica (rmSiO2) scaffold for the pinpoint delivery of siRNAs along with an anticancer drug, aiming at overcoming the drug resistance of CTGF-overexpressing breast cancer in …Author: Jie Ding, Tingxizi Liang, Ying Zhou, Zhiwei He, Qianhao Min, Liping Jiang, Junjie Zhu
https://www.sciencedirect.com/science/article/pii/S0169409X19301425
One of the first drug delivery system based on HA was the creation of an amphipathic vector hyaluronic acid-Polyethylenimine (PEI) (HAP) for gene delivery by periodic acid oxidation of hyaluronic acid and PEI [ 182 ]. This vector protects DNA from nuclease degradation, isolated …Author: Alberto Passi, Davide Vigetti
https://www.halozyme.com/enhanze/overview/default.aspx
Halozyme’s ENHANZE ® drug delivery technology is based on our patented recombinant human hyaluronidase PH20 enzyme, rHuPH20, which locally degrades hyaluronan (HA) in the subcutaneous (SC) space. This allows for increased dispersion and absorption of co-administered therapies.
Searching for Hyaluronidase Drug Delivery?
You can just click the links above. The data is collected for you.
